In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologi...
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data pr...
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to ...
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) ...
In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-nai...
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherap...
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castra...
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patie...
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive m...
Total neoadjuvant therapy (TNT) followed by rectal surgery is the standard of care in proficient mismatch repair (pMMR) locally advanced rectal cancer, but studies are finding that patients with clini...
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresecta...
Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved ...
In the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at the European Society for Medical Oncology (ESMO) Congress 2024, the PD-1 inhibitor pembrolizumab plus chemoradiotherapy, with pem...
Maeve Lowery, MD, discusses the results of the phase II DUBHE-H-308 trial, which evaluated QL1706—a bifunctional antibody consisting of iparomlimab and tuvonralimab—plus bevacizumab and/or chemotherap...
Rachna T. Shroff, MD, MS, FASCO, was the discussant for a phase III trial presented at the ESMO Congress 2024 evaluating the efficacy and safety of anlotinib plus penpulimab vs sorafenib as first-line...
Cabozantinib may be effective at improving progression-free survival in patients with previously treated neuroendocrine tumors, according to recent findings presented by Chan et al at the European Soc...
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further abo...
Josep M. Llovet, MD, PhD, presented the results of the phase III LEAP-012 trial, which evaluated the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization (TACE), during the Pre...
Retifanlimab plus platinum-based chemotherapy may benefit patients with squamous cell anal carcinoma, according to new findings presented by Rao et al at a presidential symposium at the European Socie...
Results from the multicenter double-blind randomized phase III SOLARIS trial (Alliance A021703) showed that the addition of high-dose vitamin D3 to standard treatment did not improve progression-free ...
The novel antibody-drug conjugate puxitatug samrotecan may have a manageable safety profile consistent with similar antibody-drug conjugates and demonstrated initial efficacy in patients with heavily ...
Positive results from the phase III NIAGARA trial showed perioperative treatment with the PD-L1 blocker durvalumab in combination with neoadjuvant chemotherapy demonstrated a statistically significant...
In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how ...
Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, of Humanitas Cancer Center, Milan, discuss the 5-year overall survival results from ...
Studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 reveal new groups of women with early-stage cervical1 and endometrial cancers2 who gain clinically meaningful benefit...
The results of numerous large international studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 showed that immunotherapy improves long-term overall survival in patients...
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, has confirmed the robust benefit for the STRIDE regimen of durvalumab plus tremelimumab in unresectable hepatocell...
Researchers have found that chemotherapy prior to surgery may reduce the amount of normal tissue that needs to be removed in patients with advanced nasal and paranasal sinus squamous cell carcinoma, a...
Women who breastfeed after treatment for breast cancer—including those with germline BRCA-mutated disease—may not be at increased risk of cancer recurrence or new breast cancers, according to two rece...
According to results of the first interim analysis of the phase III LEAP-012 trial, the anti–PD-1 therapy pembrolizumab plus the tyrosine kinase inhibitor lenvatinib, in combination with transarterial...